Page last updated: 2024-11-09

tacrine hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID2723754
CHEMBL ID1677
SCHEMBL ID3270
MeSH IDM0021011

Synonyms (107)

Synonym
hydroaminacrine
tacrine hydrochloride
9-acridinamine,2,3,4,-tetrahydro-, monohydrochloride
tacrin hydrochloride
nsc-72108
nsc72108
acridine,2,3,4-tetrahydro-, monohydrochloride
romotal
tenakrin
tacrine hydrochloride [usan:usp]
4966rng0bu ,
unii-4966rng0bu
t.h.a.
oros-tacrine
tha.hcl
ci-970
smr000059105
MLS000028845 ,
EU-0100036
9-amino-1,2,3,4-tetrahydroacridine hydrochloride
1684-40-8
cas-1684-40-8
NCGC00024908-02
1,2,3,4-tetrahydro-9-acridinamine monohydrochloride
9-acridinamine, 1,2,3,4-tetrahydro-, monohydrochloride
1,2,3,4-tetrahydro-9-aminoacridine hydrochloride
acridine, 9-amino-1,2,3,4-tetrahydro-, hydrochloride
einecs 216-867-5
ci 970
ccris 7250
acridine, 1,2,3,4-tetrahydro-9-amino-, monohydrochloride
9-amino-1,2,3,4-tetrahydroacridine monohydrochloride
acridine, 9-amino-1,2,3,4-tetrahydro-, monohydrochloride
nsc 72108
1,2,3,4-tetrahydroacridin-9-amine monohydrochloride
tacrine hydrochloride [usan]
MLS000758202
cpd000059105
cognex (tn)
D02068
tacrine hydrochloride (usp)
NCGC00093554-02
SPECTRUM2300104
1,2,3,4-tetrahydroacridin-9-amine hydrochloride
tetrahydroaminoacridine monohydrochloride
NCGC00093554-01
NCGC00093554-04
NCGC00093554-03
MLS001401372
A 3773
tacrine hydrochloride; tha hydrochloride
tacrine hcl
CHEMBL1677
A810973
NCGC00257853-01
dtxcid906112
dtxsid1026112 ,
1,2,3,4-tetrahydro-9-acridinamine hydrochloride
tox21_200299
nsc-759324
pharmakon1600-02300104
nsc759324
S4357
sr-01000075593
CCG-39606
FT-0633768
LP00036
AKOS015913476
tacrine hydrochloride [mart.]
tacrine hydrochloride [usp impurity]
tacrine hydrochloride [vandf]
tacrine hydrochloride [orange book]
tacrine hydrochloride [who-dd]
tacrine hydrochloride [mi]
ZUFVXZVXEJHHBN-UHFFFAOYSA-N
NC00068
SCHEMBL3270
tox21_500036
NCGC00260721-01
9-amino-1,2,3,4-tetrahydroacridine hydrochloride dihydrate
OPERA_ID_296
1,2,3,4-tetrahydroacridin-9-aminehydrochloride
mfcd00012657
HY-B1488
tacrine (hydrochloride)
CS-0013186
J-010457
SR-01000075593-3
SR-01000075593-1
SR-01000075593-9
9-acridinamine, 1,2,3,4-tetrahydro-, hydrochloride (1:1)
SW033163-6
ci970
F20766
DS-16390
1,2,3,4-tetrahydroacridin-9-amine hcl
SR-01000075593-16
AMY10870
BCP29701
tacrine hcl;hydroaminacrine; nsc72108; nsc-72108; nsc72108
Q27259239
tacrine hydrochlorid
1,2,3,4-tetrahydroacridin-9-amine;hydrochloride
1,2,3,4-tetrahydro-9-acridinamine monohydrochloride monohydrate
tacrine hydrochloride (usp impurity)
tacrine hydrochloride (mart.)
tacrine hydrochloride (usan:usp)

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Intravenous and oral 6-h blood sampling profiles in old (30 months old) and young (7 months old) rats revealed pharmacokinetic changes similar to those in humans with an approximately 40% increase in C(max) of galantamine and prolonged t(1/2) (1."( Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
Aw, CC; Browne, ER; Chen, CP; Goh, CW; Lee, JH, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (40)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency14.12540.044717.8581100.0000AID485294
Chain A, HADH2 proteinHomo sapiens (human)Potency15.84890.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency15.84890.025120.237639.8107AID893
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
acetylcholinesteraseHomo sapiens (human)Potency1.72500.002541.796015,848.9004AID1347395; AID1347397; AID1347398; AID1347399
ClpPBacillus subtilisPotency31.62281.995322.673039.8107AID651965
ATAD5 protein, partialHomo sapiens (human)Potency7.30780.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency17.35820.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency11.56560.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency41.64170.000221.22318,912.5098AID588516; AID743035; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency25.11890.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency54.48270.001022.650876.6163AID1224838; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency54.48270.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency15.84890.000817.505159.3239AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency59.80100.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency48.55770.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency32.78270.000229.305416,493.5996AID588513; AID743069; AID743078; AID743079; AID743080; AID743091
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency56.23410.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency12.09350.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency76.95880.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency0.00190.143427.612159.8106AID1159516
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency1,000.00000.010039.53711,122.0200AID1479
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency19.32180.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency30.63790.000323.4451159.6830AID743067
mitogen-activated protein kinase 1Homo sapiens (human)Potency1.25890.039816.784239.8107AID1454
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency47.15460.000627.21521,122.0200AID651741; AID743219
gemininHomo sapiens (human)Potency14.61930.004611.374133.4983AID624296; AID624297
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency14.12540.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency68.58960.002319.595674.0614AID651631; AID720552
TAR DNA-binding protein 43Homo sapiens (human)Potency6.30961.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseElectrophorus electricus (electric eel)IC50 (µMol)0.08880.00000.94539.9400AID303069; AID601099; AID623717; AID701330
Collagenase 3Bos taurus (cattle)IC50 (µMol)0.04390.00030.01060.0439AID241561
CholinesteraseHomo sapiens (human)IC50 (µMol)0.04300.00001.559910.0000AID1436087; AID241561; AID404844; AID44290
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)0.31630.00000.933210.0000AID1436088; AID241531; AID303071; AID31493; AID404843; AID592640; AID623718; AID674795
AcetylcholinesteraseHomo sapiens (human)Ki0.16300.00001.27869.7300AID674798; AID674799
Acetylcholinesterase Bos taurus (cattle)IC50 (µMol)0.13000.00000.61068.7000AID241860; AID30689; AID404842
CholinesteraseEquus caballus (horse)IC50 (µMol)0.01890.00002.22149.4000AID601100; AID701329
Carboxylic ester hydrolase Rattus norvegicus (Norway rat)IC50 (µMol)0.09200.00041.48119.8700AID44440
Carboxylic ester hydrolase Equus caballus (horse)IC50 (µMol)0.01900.00512.69848.5000AID592641
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (168)

Processvia Protein(s)Taxonomy
proteolysisCollagenase 3Bos taurus (cattle)
extracellular matrix disassemblyCollagenase 3Bos taurus (cattle)
collagen catabolic processCollagenase 3Bos taurus (cattle)
bone morphogenesisCollagenase 3Bos taurus (cattle)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (54)

Processvia Protein(s)Taxonomy
endopeptidase activityCollagenase 3Bos taurus (cattle)
metalloendopeptidase activityCollagenase 3Bos taurus (cattle)
calcium ion bindingCollagenase 3Bos taurus (cattle)
collagen bindingCollagenase 3Bos taurus (cattle)
zinc ion bindingCollagenase 3Bos taurus (cattle)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
amyloid-beta bindingAcetylcholinesterase Bos taurus (cattle)
protein bindingAcetylcholinesterase Bos taurus (cattle)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (40)

Processvia Protein(s)Taxonomy
extracellular matrixCollagenase 3Bos taurus (cattle)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesterase Bos taurus (cattle)
side of membraneAcetylcholinesterase Bos taurus (cattle)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (156)

Assay IDTitleYearJournalArticle
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1220485Half life in human at 2 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID701323Vasorelaxant activity in rat aortic rings assessed as reduction of norepinephrine-induced contraction2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID1220466Oral bioavailability in 7 months-old Lister Hooded rat at 3 mg/kg2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID701329Inhibition of equine serum BuChE using butyrylthiocholine iodide as substrate after 5 mins by Ellman's method2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID241561Inhibitory concentration against Butyrylcholinesterase from human erythrocytes2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors.
AID1220482Toxicity in 7 months-old Lister Hooded rat assessed as decrease in rectal temperature at 30 mg/kg, po after 0.5 hrs relative to control2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220507Toxicity in 30 months-old Lister Hooded rat assessed as enhancement of salivation at 10 mg/kg, po after 6 hrs relative to control2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID404842Inhibition of bovine erythrocyte AChE by Ellman's assay2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
AID303071Inhibition of human Acetylcholinesterase2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
AID1382567Hepatotoxicity in ICR mouse assessed as serum ALT level at 12.82 umol/100 g body weight administered orally and measured after 36 hrs (Rvb = 27.8 +/- 1.8 U/L)2018European journal of medicinal chemistry, Mar-25, Volume: 148Synthesis and activity towards Alzheimer's disease in vitro: Tacrine, phenolic acid and ligustrazine hybrids.
AID1220506Toxicity in 30 months-old Lister Hooded rat assessed as subtle tremor in limbs and hypothermia at 10 mg/kg, po after 6 hrs relative to control2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220476Dose normalized AUC (0 to t) in 30 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID592640Inhibition of human AChE incubated with compounf for 5 mins before addition of substrate acetylthiocholine iodide by Ellman's method2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Aβ-aggregation inhibitors.
AID1220463Tmax in 7 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1220472Dose normalized AUC (0 to t) in 30 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1382566Hepatotoxicity in ICR mouse assessed as serum ALT level at 12.82 umol/100 g body weight administered orally and measured after 24 hrs (Rvb = 37.3 +/- 2.9 U/L)2018European journal of medicinal chemistry, Mar-25, Volume: 148Synthesis and activity towards Alzheimer's disease in vitro: Tacrine, phenolic acid and ligustrazine hybrids.
AID592645Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 24 hrs by MTT-based colorimetric assay2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Aβ-aggregation inhibitors.
AID1220460Dose normalized AUC (0 to t) in 7 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID32092Inhibition of acetylcholinesterase activity in rat cerebral cortex homogenate, in the presence of a specific butyrylcholinesterase (BChE) inhibitor; ethopropazine1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Heterodimeric tacrine-based acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions.
AID1220465Dose normalized AUC (0 to infinity) in 7 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID404847Inhibition of human AChE assessed as reduction of thioflavin T fluorescence at 100 uM2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
AID1220464Dose normalized AUC (0 to t) in 7 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID303073Selectivity for human butyrylcholinesterase over human butyrylcholinesterase2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1382568Hepatotoxicity in ICR mouse assessed as serum AST level at 12.82 umol/100 g body weight administered orally and measured after 8 hrs (Rvb = 25.5 +/- 1.6 U/L)2018European journal of medicinal chemistry, Mar-25, Volume: 148Synthesis and activity towards Alzheimer's disease in vitro: Tacrine, phenolic acid and ligustrazine hybrids.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID701316Hepatotoxicity in ICR mouse assessed as serum ALT level at 11.86 umol, id measured at 30 hrs (Rvb = 27.4 +/- 2.3 U/L)2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID1542257Inhibition of equine butyrylcholinesterase using butyrylthiocholine iodide as substrate incubated for 10 mins by Ellman's method2019European journal of medicinal chemistry, Apr-01, Volume: 167Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
AID1220470Half life in 30 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID30689In vitro inhibitory concentration against bovine acetylcholinesterase enzyme2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Synthesis, in vitro pharmacology, and molecular modeling of syn-huprines as acetylcholinesterase inhibitors.
AID1220500Drug uptake in 7 months-old Lister Hooded rat assessed as corrected brain concentration at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1382565Hepatotoxicity in ICR mouse assessed as serum ALT level at 12.82 umol/100 g body weight administered orally and measured after 8 hrs (Rvb = 40.9 +/- 2.2 U/L)2018European journal of medicinal chemistry, Mar-25, Volume: 148Synthesis and activity towards Alzheimer's disease in vitro: Tacrine, phenolic acid and ligustrazine hybrids.
AID1220457Volume of distribution in 7 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220479Inhibition of cholinesterase activity in 7 months-old Lister Hooded rat brain at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220489Drug excretion in human urine at 2 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1220508Toxicity in 30 months-old Lister Hooded rat assessed as enhancement of salivation at 30 mg/kg, po after 6 hrs relative to control2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID701317Hepatotoxicity in ICR mouse assessed as serum ALT level at 11.86 umol, id measured at 20 hrs (Rvb = 34.1 +/- 1.8 U/L)2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID233877Selectivity for Acetylcholinesterase (AChE); ratio of BChE IC50 to AChE IC501999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Heterodimeric tacrine-based acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions.
AID44440Inhibition of rat serum butyrylcholinesterase, in the presence of a specific AChE inhibitor; BW284c511999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Heterodimeric tacrine-based acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions.
AID303069Inhibition of Electrophorus electricus Acetylcholinesterase2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
AID1220504Ratio of brain to blood in 30 months-old Lister Hooded rat blood at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID674799Inhibition of human recombinant AChE assessed as dissociation constant for enzyme-inhibitor-substrate complex using acetylthiocholine substrate preincubated for 5 mins before substrate addition by Ellman's method2012European journal of medicinal chemistry, Sep, Volume: 55Synthesis, design and biological evaluation of novel highly potent tacrine congeners for the treatment of Alzheimer's disease.
AID601104Antioxidant activity against AAPH-induced peroxyl radical assessed as trolox equivalent at 1 to 5 uM after 15 mins by oxygen radical absorbance capacity-fluorescein assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and evaluation of heterobivalent tacrine derivatives as potential multi-functional anti-Alzheimer agents.
AID1220503Drug uptake in 30 months-old Lister Hooded rat assessed as corrected brain concentration at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220497Inhibition of acetylcholinesterase activity in 30 months-old Lister Hooded rat brain assessed as percent enhancement of inhibition at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220458Half life in 7 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220495Inhibition of butyrylcholinesterase activity in 7 months-old Lister Hooded rat brain at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID44290In vitro inhibitory concentration against BChE of human serum2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Synthesis, in vitro pharmacology, and molecular modeling of syn-huprines as acetylcholinesterase inhibitors.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1220480Inhibition of cholinesterase activity in 7 months-old Lister Hooded rat plasma at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID229310Ratio of IC50 of bovine AChE to IC50 of human AChE was determined2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Synthesis, in vitro pharmacology, and molecular modeling of syn-huprines as acetylcholinesterase inhibitors.
AID1220501Ratio of brain to blood in 7 months-old Lister Hooded rat blood at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID701313Hepatotoxicity in rat assessed as change in cell morphology after 30 hrs by HE staining2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID1220461Dose normalized AUC (0 to infinity) in 7 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220499Drug uptake in 7 months-old Lister Hooded rat blood at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID674796Inhibition of human plasmatic BChE using butylthiocholne substrate preincubated for 5 mins before substrate addition by Ellman's method2012European journal of medicinal chemistry, Sep, Volume: 55Synthesis, design and biological evaluation of novel highly potent tacrine congeners for the treatment of Alzheimer's disease.
AID404843Inhibition of human erythrocyte AChE by Ellman's assay2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
AID1220478Oral bioavailability in 30 months-old Lister Hooded rat at 3 mg/kg2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID303070Inhibition of Torpedo californica Acetylcholinesterase2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
AID1220505Toxicity in 7 months-old Lister Hooded rat assessed as subtle tremor in limbs and hypothermia at 10 mg/kg, po after 6 hrs relative to control2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID623718Inhibition of human recombinant AChE using acetylthiocholine iodide as substrate by spectrophotometric method2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Benzofurans from Styrax agrestis as acetylcholinesterase inhibitors: structure-activity relationships and molecular modeling studies.
AID1651235Inhibition of BuChE (unknown origin) at 20 nM relative to control2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Selective acetylcholinesterase inhibitors derived from muscle relaxant dantrolene.
AID241531Inhibitory concentration against Acetylcholinesterase from human erythrocytes2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors.
AID701320Cognitive enhancing effect in ICR mouse assessed as reversal of scopolamine-induced memory deficit by measuring time taken for latency time at 1.978 umol, id administered 55 mins before scopolamine challenge measured during 300 secs of first trial in pres2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID1220502Drug uptake in 30 months-old Lister Hooded rat blood at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID701330Inhibition of eel AChE using acetylthiocholine iodide as substrate after 5 mins by Ellman's method2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID1436087Inhibition of human BuChE using S-butyrylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition measured for 60 to 300 secs by Ellman's method2017European journal of medicinal chemistry, Jan-27, Volume: 1262,4-Disubstituted quinazolines as amyloid-β aggregation inhibitors with dual cholinesterase inhibition and antioxidant properties: Development and structure-activity relationship (SAR) studies.
AID1220477Dose normalized AUC (0 to infinity) in 30 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID32128Inhibitory activity against rat brain Acetylcholinesterase using rat cortex homogenate relative to Tacrine.1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Heterodimeric tacrine-based acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions.
AID1651231Inhibition of AChE (unknown origin) at 0.1 uM using acetylthiocholine iodide as substrate by Ellman's method relative to control2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Selective acetylcholinesterase inhibitors derived from muscle relaxant dantrolene.
AID1220488Oral bioavailability in human at 2 mg single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220483Plasma protein binding in human at 2 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID674797Selectivity index, ratio of IC50 for human plasmatic BChE to IC50 for human recombinant AChE2012European journal of medicinal chemistry, Sep, Volume: 55Synthesis, design and biological evaluation of novel highly potent tacrine congeners for the treatment of Alzheimer's disease.
AID701314Hepatotoxicity in ICR mouse assessed as serum ASAT level at 11.86 umol, id measured at 20 hrs (Rvb = 21.5 +/- 1.5 U/L)2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID1436088Inhibition of human AChE using acetylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition measured for 60 to 300 secs by Ellman's method2017European journal of medicinal chemistry, Jan-27, Volume: 1262,4-Disubstituted quinazolines as amyloid-β aggregation inhibitors with dual cholinesterase inhibition and antioxidant properties: Development and structure-activity relationship (SAR) studies.
AID1220513Blood clearance in 7 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220510Toxicity in 30 months-old Lister Hooded rat assessed as lacrimation at 30 mg/kg, po after 0.5 hrs relative to control2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID601101Selectivity index, ratio of IC50 for electric eel AChE to IC50 for equine serum BuChE2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and evaluation of heterobivalent tacrine derivatives as potential multi-functional anti-Alzheimer agents.
AID1220496Inhibition of butyrylcholinesterase activity in 7 months-old Lister Hooded rat plasma at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID592642Selectivity index, ratio of IC50 for human AChE to IC50 for equine BChE2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Aβ-aggregation inhibitors.
AID1220468Blood clearance in 30 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220491Drug excretion in human feces at 2 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220467Cmax in 30 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID701328Selectivity ratio of IC50 for eel AChE to IC50 for equine serum BuChE2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID1220512Cmax in 7 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID701315Hepatotoxicity in ICR mouse assessed as serum ASAT level at 11.86 umol, id measured at 8 hrs (Rvb = 24.3 +/- 2 U/L)2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID1220486Volume of distribution in human at 2 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID701319Cognitive enhancing effect in ICR mouse assessed as reversal of scopolamine-induced memory deficit by measuring time taken for latency time at 1.978 umol, id administered 55 mins before scopolamine challenge measured during second trial done after 24 hrs 2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID674798Inhibition of human recombinant AChE assessed as dissociation constant for enzyme-inhibitor complex using acetylthiocholine substrate preincubated for 5 mins before substrate addition by Ellman's method2012European journal of medicinal chemistry, Sep, Volume: 55Synthesis, design and biological evaluation of novel highly potent tacrine congeners for the treatment of Alzheimer's disease.
AID1220473Dose normalized AUC (0 to infinity) in 30 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID404848Inhibition of human recombinant AChE-induced amyloid beta 1-40 aggregation at 100 uM2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
AID1382570Hepatotoxicity in ICR mouse assessed as serum AST level at 12.82 umol/100 g body weight administered orally and measured after 36 hrs (Rvb = 18.5 +/- 1.7 U/L)2018European journal of medicinal chemistry, Mar-25, Volume: 148Synthesis and activity towards Alzheimer's disease in vitro: Tacrine, phenolic acid and ligustrazine hybrids.
AID303072Inhibition of human butyrylcholinesterase2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
AID592641Inhibition of equine BChE incubated with compounf for 5 mins before addition of substrate S-butyrylthiocholine iodide by Ellman's method2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Aβ-aggregation inhibitors.
AID1220462Cmax in 7 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220475Tmax in 30 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID601100Inhibition of equine serum BuChE assessed as inhibition of butyrylthiocholine chloride substrate hydrolysis incubated for 15 mins before substrate addition measured by spectrophotometry2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and evaluation of heterobivalent tacrine derivatives as potential multi-functional anti-Alzheimer agents.
AID1220474Cmax in 30 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220469Volume of distribution in 30 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220484Tmax in human at 2 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1382569Hepatotoxicity in ICR mouse assessed as serum AST level at 12.82 umol/100 g body weight administered orally and measured after 24 hrs (Rvb = 20.8 +/- 2.2 U/L)2018European journal of medicinal chemistry, Mar-25, Volume: 148Synthesis and activity towards Alzheimer's disease in vitro: Tacrine, phenolic acid and ligustrazine hybrids.
AID1220487Clearance in human at 2 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220509Toxicity in 7 months-old Lister Hooded rat assessed as lacrimation at 30 mg/kg, po after 2 hrs relative to control2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID31493In vitro inhibitory concentration against acetylcholinesterase of human erythrocytes2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Synthesis, in vitro pharmacology, and molecular modeling of syn-huprines as acetylcholinesterase inhibitors.
AID701324Induction of NO release in phosphate buffer assessed as inorganic nitrite level at pH 7.4 at 10'-4 M after 1.5 hrs by Griess assay in presence of L-cysteine2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID404844Inhibition of human serum BChE by Ellman's assay2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
AID229324Ratio of IC50 of human BChE to IC50 of human AChE was determined2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Synthesis, in vitro pharmacology, and molecular modeling of syn-huprines as acetylcholinesterase inhibitors.
AID601099Inhibition of electric eel AChE assessed as inhibition of acetylthiocholine chloride substrate hydrolysis incubated for 15 mins before substrate addition measured by spectrophotometry2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis and evaluation of heterobivalent tacrine derivatives as potential multi-functional anti-Alzheimer agents.
AID1220471Mean residence time in 30 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID623717Inhibition of electric eel AChE using acetylthiocholine iodide as substrate by spectrophotometric method2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Benzofurans from Styrax agrestis as acetylcholinesterase inhibitors: structure-activity relationships and molecular modeling studies.
AID1220459Mean residence time in 7 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220511Toxicity in 30 months-old Lister Hooded rat assessed as decrease in rectal temperature at 10 mg/kg, po after 1 hr relative to control2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID701312Hepatotoxicity in ICR mouse assessed as serum ASAT level at 11.86 umol, id measured at 30 hrs (Rvb = 23.8 +/- 1.3 U/L)2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID241860Inhibitory concentration against Acetylcholinesterase from bovine erythrocytes2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors.
AID674795Inhibition of human recombinant AChE using acetylthiocholine substrate preincubated for 5 mins before substrate addition by Ellman's method2012European journal of medicinal chemistry, Sep, Volume: 55Synthesis, design and biological evaluation of novel highly potent tacrine congeners for the treatment of Alzheimer's disease.
AID701318Hepatotoxicity in ICR mouse assessed as serum ALT level at 11.86 umol, id measured at 8 hrs (Rvb = 18.8 +/- 1.3 U/L)2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (3.23)18.2507
2000's7 (22.58)29.6817
2010's18 (58.06)24.3611
2020's5 (16.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.86 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index5.55 (4.65)
Search Engine Demand Index47.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (96.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]